A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer

Han, Sehwan; Kim, Sung‐Bae; Kang, Sung Soo; Noh, Woo-Chul; Paik, Nam-Sun; Chang, Eilsung; Kim, Je-Ryong; Lim, Sook-Hyun; Park, Hee-Sook

doi:10.1007/s10549-005-9131-6

Cited by 15 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 1 shows the scheme for this study protocol. This regimen is known to be effective as neoadjuvant chemotherapy for stage II or III breast cancer [14,15,21]. We performed retrospective descriptive analysis for PET/CTs within this prospective study.…”

Section: Methodsmentioning

confidence: 99%

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

Keam

Koh

et al. 2011

BMC Cancer

View full text Add to dashboard Cite

BackgroundThis study was aimed 1) to investigate the predictive value of FDG PET/CT (fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography) for histopathologic response and 2) to explore the results of FDG PET/CT by molecular phenotypes of breast cancer patients who received neoadjuvant chemotherapy.MethodsSeventy-eight stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. FDG PET/CTs were acquired before chemotherapy and after the first cycle of chemotherapy for evaluating early metabolic response.ResultsThe mean pre- and post-chemotherapy standard uptake value (SUV) were 7.5 and 3.9, respectively. The early metabolic response provided by FDG PET/CT after one cycle of neoadjuvant chemotherapy was correlated with the histopathologic response after completion of neoadjuvant chemotherapy (P = 0.002). Sensitivity and negative predictive value were 85.7% and 95.1%, respectively. The estrogen receptor negative phenotype had a higher pre-chemotherapy SUV (8.6 vs. 6.4, P = 0.047) and percent change in SUV (48% vs. 30%, P = 0.038). In triple negative breast cancer (TNBC), the pre-chemotherapy SUV was higher than in non-TNBC (9.8 vs. 6.4, P = 0.008).ConclusionsThe early metabolic response using FDG PET/CT could have a predictive value for the assessment of histopathologic non-response of stage II/III breast cancer treated with neoadjuvant chemotherapy. Our findings suggest that the initial SUV and the decline in SUV differed based on the molecular phenotype.Trial RegistrationClinicalTrials.gov: NCT01396655

show abstract

Section: Methodsmentioning

confidence: 99%

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

Keam

Koh

et al. 2011

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…This regimen is known to be effective and well-tolerated as neoadjuvant chemotherapy for stage II or III breast cancer [19,21]. After completion of neoadjuvant treatment, the patients underwent curative surgery, either breast-conserving surgery or mastectomy with axillary lymph node dissection [19].…”

Section: Patients and Treatmentmentioning

confidence: 99%

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

Keam

Kim

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…With the combination of doxorubicin and docetaxel as neoadjuvant chemotherapy for LABC, the overall clinical response rate achieved ranges from 86 to 90%, with a pCR between 10.5 and 16.6% [6,7]. In a phase II trial the pCR rate attained in women with stage II to III breast cancer treated with neoadjuvant docetaxel and capecitabine was 26.9% [8].…”

Section: Introductionmentioning

confidence: 99%

Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer

Abstract: Docetaxel and doxorubicin was an effective and well-tolerated neoadjuvant chemotherapy for stage II and III breast cancer. Clinical benefit of this treatment will be confirmed by survival data with long term follow up.

Cited by 15 publications

References 18 publications

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer

Contact Info

Product

Resources

About